Abstracts tagged "giant cell arteritis"

Abstract Number: 0494 • ACR Convergence 2022
Risk for Visual Loss in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹, Lene Kristin Brekke², Tanaz Kermani³, Oyvind Molberg⁴ and Andreas Diamantopoulos⁵, ¹Martina Hansens Hospital, Hosle, Norway, ²Haugesund Revmatismesykehus, Haugesund, Nepal, ³University of California Los Angeles, West Hills, CA, ⁴Oslo University Hospital, Oslo, Nepal, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Permanent visual loss is a feared complication reported in up to 19% of…
Abstract Number: 1620 • ACR Convergence 2022
Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Alwin Sebastian¹, alessandro tomelleri², PIERLUIGI MACCHIONI³, Giulia Klinowski³, Carlo Salvarani⁴, Abdul Kayani⁵, Mohammad Tariq⁵, Diana Prieto-Peña⁶, Edoardo Conticini⁷, Muhammad Khurshid⁸, Sue Inness⁹, Jo Jackson⁹, Kornelis van der Geest¹⁰ and Bhaskar Dasgupta⁵, ¹University Hospital Limerick, Dooradoyle, Ireland, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ³IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁴Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁵Mid and South Essex University Hospital Groups, Southend, United Kingdom, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁸University Hospital Dorset, NHS foundation trust, UK, Poole, United Kingdom, ⁹University of Essex, School of Sport, Rehabilitation and Exercise science, Colchester, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for…
Abstract Number: 0462 • ACR Convergence 2022
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
Mohanad Elfishawi¹, Mahmut Kaymakci², Sara Achenbach³, Cynthia Crowson⁴, Tanaz Kermani⁵, Cornelia Weyand⁴, Matthew J. Koster¹ and Kenneth J. Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
Abstract Number: 0479 • ACR Convergence 2022
A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA
Colm Kirby¹, Rachael Flood¹, Ronan Mullan¹, Grainne Murphy² and David Kane¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Cork University Hospital, Cork, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) has become a reliable alternative to biopsy for diagnosing GCA. However, normalisation of pathologic findings have been…
Abstract Number: 0495 • ACR Convergence 2022
Seasonal Variation in the Incidence of GCA in the UK and Ireland
Leah Rooney¹, Lorraine O'Neill¹ and Eamonn Molloy², ¹St Vincent's University Hospital, Dublin, Ireland, ²St Vincent's Healthcare Group, Dublin, Ireland
Background/Purpose: Giant Cell Arteritis (GCA) is the most common primary systemic vasculitis in adults, occurring in individuals over age 50, most frequently in women (3:1,…
Abstract Number: 0463 • ACR Convergence 2022
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive…
Abstract Number: 0480 • ACR Convergence 2022
Treatment of Giant Cell Arteritis Patients with Ultra-short Glucocorticoids and Tocilizumab: Role of Imaging in a Prospective Study
Francesco Muratore¹, Giulia Cassone², Chiara Marvisi³, ELENA GALLI¹, Luigi Boiardi¹, GIULIA BESUTTI¹, Lucia Spaggiari¹, MASSIMILIANO CASALI¹, Pamela Mancuso¹, Annibale Versari¹, Paolo Giorgi Rossi¹ and Carlo Salvarani⁴, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Università di Modena e Reggio Emilia, Modena, Italy, ³Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To evaluate the clinical and functional/morphological imaging response in a series of active large vessel (LV)-GCA patients treated with tocilizumab (TCZ) monotherapy after ultra-short-term…
Abstract Number: 0496 • ACR Convergence 2022
Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
Diogo Esperança Almeida¹, Kate Smith², Borsha Sarker², Andrew Barr³, Richard Wakefield⁴ and Sarah Mackie⁴, ¹Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, ²National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; 4. Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: To determine if disease extent on ultrasound (US) of temporal and axillary arteries predicts a relapsing course of giant cell arteritis (GCA).Methods: We conducted…
Abstract Number: 0465 • ACR Convergence 2022
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
Diana Prieto-Peña¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, Pilar Bernabeu⁵, Paloma Vela-Casampere⁶, F. Javier Narváez⁷, Vicente Aldasoro⁸, Olga Maíz⁹, Jesús Carlos Fernández-López¹⁰, Mercedes Freire¹⁰, Rafael Melero¹¹, Juan Ignacio Villa¹², Beatriz Gonzalez-Alvarez¹³, Roser Solans-Laqué¹⁴, José Luis Callejas¹⁵, Carlos Fernandez-Diaz¹⁶, Salvador Garcia-Morillo¹⁷, Mauricio Minguez¹⁸, Cristina Fernández-Carballido¹⁹, Esteban Rubio²⁰, Eugenio De Miguel²¹, Julio Sánchez-Martín²², Esther Fernandez²³, Sheila Melchor²⁴, Eva Salgado-Pérez²⁵, Beatriz Bravo²⁶, Susana Romero Yuste²⁷, Eva Galíndez-Agirregoikoa²⁸, francisca Sivera²⁹, Ivan Ferraz Amaro³⁰, Cristina Hidalgo³¹, Carlos Romero Gomez³², Carles Galisteo³³, Patricia Moya Alvarado³⁴, Noelia Alvarez-Rivas³⁵, Javier Mendizabal³⁶, Juan Carlos Nieto González³⁷, Juan Ramón de Dios³⁸, Jose Luis Andreu³⁹, Nagore Fernandez-Llanio⁴⁰, Eztizen Labrador⁴¹, Enrique Raya Álvarez⁴², Arantxa Conesa⁴³, Francisco Ortiz-Sanjuan⁴⁴, Sara Manrique Arija³², Iñigo Rua-Figueroa⁴⁵, A. García-valle⁴⁶, Miguel Ángel González-Gay⁴⁷ and Ricardo Blanco², ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Hospital General de Alicante, Alicante, Spain, ⁶Hospital General Universitario Alicante, Alicante, Spain, ⁷Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario de Navarra, Pamplona, Spain, ⁹Hospital Univesitario de Donostia, Donostia, Spain, ¹⁰Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹²Hospital Sierrallana, Torrelavega, Spain, ¹³Hospital Nuestra Señora de la Candelaria, Tenerife, Spain, ¹⁴Hospital Vall d’Hebron, Barcelona, Spain, ¹⁵Hospital San Cecilio, Granada, Spain, ¹⁶H, Murcia, Spain, ¹⁷Hospital Virgen del Rocío, Sevilla, Spain, ¹⁸San Juan de Alicante, Alicante, Spain, ¹⁹Agencia Valenciana de Salud, Alicante, Spain, ²⁰HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, Spain, ²¹Hospital Universitario La Paz, Madrid, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ²⁶Hospital Virgen de las Nieves, Madrid, Spain, ²⁷Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Elda, Alicante, Spain, ³⁰Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Regional Universitario Málaga, Málaga, Spain, ³³Hospital Parc Tauli,, Sabadel, Spain, ³⁴Hospital Parc Tauli, Barcelona, Spain, ³⁵Hospital San Agustin, Aviles, Spain, ³⁶Complejo Hospitalario de Navarra,, Pamplona, Spain, ³⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁸Hospital de Araba, Araba, Spain, ³⁹Hospital Puerta de Hierro, Madrid, Spain, ⁴⁰Hospital Arnau de Vilanova,, València, Spain, ⁴¹Hospital San Pedro, Logroño, Spain, ⁴²Hospital Universitario San Cecilio, Granada, Spain, ⁴³Hospital Universitario de Castellón, València, Spain, ⁴⁴Hospital Universitario de La Fe, València, Spain, ⁴⁵Hospital Doctor Negrín, Gran Canaria, Spain, ⁴⁶Completo Asistencial Palencia, Palencia, Spain, ⁴⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). However, LVV-GCA and TAK…
Abstract Number: 0481 • ACR Convergence 2022
Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
Francesca Regola¹, Jacopo Mora¹, Giovanni Bosio², Laura Andreoli¹, Franco Franceschini¹ and Paola Toniati¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Oral glucocorticoids (GC) are the mainstay of treatment for giant cell arteritis (GCA) but chronic exposure to GC is associated with serious comorbidities. The…
Abstract Number: 0497 • ACR Convergence 2022
Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis
Victor Yang¹, Christopher McMaster¹, Claire Owen², Jessica Leung³, Bonnia Liu¹, Russell Buchanan⁴ and David Liew⁴, ¹Austin Health, Melbourne, Australia, ²Austin Health, Malvern East, Australia, ³Austin Health, Preston, Victoria, Australia, ⁴Austin Health, Heidelberg, Australia
Background/Purpose: The 2022 ACR/EULAR GCA classification criteria are a major advance which will underpin future scientific advancement by classifying patients already diagnosed with primary systemic…
Abstract Number: 0466 • ACR Convergence 2022
Assessment of Probability Scores to Predict Giant Cell Arteritis
Chadi Sargi¹, Stephanie Ducharme-Benard², Valerie Benard³, Rosalie-Selene Meunier⁴, Carolyn Ross⁵ and Jean-Paul Makhzoum⁶, ¹University of Montreal, Laval, Canada, ²Hopital Sacre-Coeur, Montréal, QC, Canada, ³University of Montreal, Saint-Ambroise-de-Kildare, Canada, ⁴Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁵University of Montreal, Montréal, QC, Canada, ⁶Hopital du Sacre-Coeur de Montreal, Montréal, QC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis but remains challenging to diagnose. In the past years, many probability tools have been…
Abstract Number: 0482 • ACR Convergence 2022
Role of miR-146a and miR-146b in Giant Cell Arteritis
Martina Bonacini¹, Alessandro Rossi¹, Ilaria Ferrigno², Francesco Muratore¹, Luigi Boiardi¹, Alberto Cavazza¹, Luca Cimino², Angelo Ghidini¹, Giuseppe Malchiodi¹, Marc Corbera-Bellalta³, Maria C Cid³, Alessandro Zerbini¹, Carlo Salvarani⁴ and Stefania Croci¹, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, ³Hospital Clinic, University of Barcelona, Barcelona, Spain, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large and medium-sized arteries. MiRNAs (miR) are small, non-coding RNAs that inhibit gene expression at…
Abstract Number: 0580 • ACR Convergence 2022
18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis
Samuel Deshayes¹, Caroline Baugé², Pierre-Antoine Dupont², Christophe Simard², Hubert De Boysson¹, Alain Manrique² and Achille Aouba¹, ¹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²UR4650 PSIR, Normandie Univ, UNICAEN, Caen, France
Background/Purpose: Metabolic imaging is routinely used to demonstrate aortitis in patients with giant-cell arteritis. We aimed to investigate aortitis in BALB/c IL1rn-/- mice, a preclinical…
Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Jacob Sode¹, Jens Rathmann¹, Anna Wilding², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].